{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T14:26:58Z","timestamp":1773671218774,"version":"3.50.1"},"reference-count":19,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jiac-j.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection and Chemotherapy"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1016\/j.jiac.2017.12.022","type":"journal-article","created":{"date-parts":[[2018,2,4]],"date-time":"2018-02-04T08:51:36Z","timestamp":1517734296000},"page":"476-478","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["A potential drug interaction between phenobarbital and dolutegravir: A case report"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4850-7631","authenticated-orcid":false,"given":"Shinichi","family":"Hikasa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihiro","family":"Sawada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hitomi","family":"Seino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shota","family":"Shimabukuro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyoko","family":"Hideta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noriko","family":"Uwa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Higasa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tazuko","family":"Tokugawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jiac.2017.12.022_bib1","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/S0026-895X(25)08713-9","article-title":"Modulators and substrates of p-glycoprotein and cytochrome p4503a coordinately up-regulate these proteins in human colon carcinoma cells","volume":"49","author":"Schuetz","year":"1996","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.jiac.2017.12.022_bib2","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1111\/j.0013-9580.2004.12704.x","article-title":"Phenobarbital for the treatment of epilepsy in the 21st century: a critical review","volume":"45","author":"Kwan","year":"2004","journal-title":"Epilepsia"},{"key":"10.1016\/j.jiac.2017.12.022_bib3","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1097\/01.qai.0000234089.41785.c8","article-title":"Brief report: enzyme inducers reduce elimination half-life after a single dose of nevirapine in healthy women","volume":"43","author":"L'Homme","year":"2006","journal-title":"J\u00a0Acquir Immune Defic Syndr"},{"key":"10.1016\/j.jiac.2017.12.022_bib4","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1086\/523722","article-title":"Clinically significant drug interaction between tipranavir-ritonavir and phenobarbital in an hiv-infected subject","volume":"45","author":"Bonora","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jiac.2017.12.022_bib5","article-title":"A\u00a0case of a potential drug interaction between phenobarbital and darunavir-based antiretroviral therapy","volume":"7","author":"Naccarato","year":"2016","journal-title":"J\u00a0AIDS Clin Res"},{"key":"10.1016\/j.jiac.2017.12.022_bib6","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S1474-4422(03)00409-5","article-title":"Clinically important drug interactions in epilepsy: general features and interactions between antiepileptic drugs","volume":"2","author":"Patsalos","year":"2003","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.jiac.2017.12.022_bib7","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1124\/dmd.106.012047","article-title":"Effects of green tea compounds on irinotecan metabolism","volume":"35","author":"Mirkov","year":"2007","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.jiac.2017.12.022_bib8","doi-asserted-by":"crossref","first-page":"3536","DOI":"10.1128\/AAC.00292-13","article-title":"Metabolism, excretion, and mass balance of the hiv-1 integrase inhibitor dolutegravir in humans","volume":"57","author":"Castellino","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2017.12.022_bib9","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1097\/QAI.0b013e318276cda9","article-title":"Safety, tolerability, and pharmacokinetics of the hiv integrase inhibitor dolutegravir given twice daily with rifampin or once daily with rifabutin: results of a phase 1 study among healthy subjects","volume":"62","author":"Dooley","year":"2013","journal-title":"J\u00a0Acquir Immune Defic Syndr"},{"key":"10.1016\/j.jiac.2017.12.022_bib10","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1007\/s00228-014-1732-8","article-title":"Effects of enzyme inducers efavirenz and tipranavir\/ritonavir on the pharmacokinetics of the hiv integrase inhibitor dolutegravir","volume":"70","author":"Song","year":"2014","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.jiac.2017.12.022_bib11","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1007\/s00228-016-2020-6","article-title":"Effect of carbamazepine on dolutegravir pharmacokinetics and dosing recommendation","volume":"72","author":"Song","year":"2016","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.jiac.2017.12.022_bib12","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1124\/dmd.112.048918","article-title":"In\u00a0vitro investigations into the roles of drug transporters and metabolizing enzymes in the disposition and drug interactions of dolutegravir, a hiv integrase inhibitor","volume":"41","author":"Reese","year":"2013","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.jiac.2017.12.022_bib13","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1172\/JCI6663","article-title":"The role of intestinal p-glycoprotein in the interaction of digoxin and rifampin","volume":"104","author":"Greiner","year":"1999","journal-title":"J\u00a0Clin Investig"},{"key":"10.1016\/j.jiac.2017.12.022_bib14","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.2174\/138161208784746798","article-title":"Clinical drugs that interact with st. John's wort and implication in drug development","volume":"14","author":"Di","year":"2008","journal-title":"Curr Pharmaceut Des"},{"key":"10.1016\/j.jiac.2017.12.022_bib15","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1128\/AAC.05739-11","article-title":"Effect of food on the pharmacokinetics of the integrase inhibitor dolutegravir","volume":"56","author":"Song","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2017.12.022_bib16","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1007\/s40262-013-0093-2","article-title":"Clinical pharmacokinetic, pharmacodynamic and drug-interaction profile of the integrase inhibitor dolutegravir","volume":"52","author":"Cottrell","year":"2013","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.jiac.2017.12.022_bib17","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1007\/s00228-014-1719-5","article-title":"Impact of cytochrome p450 inducers with or without inhibitors on the serum clobazam level in patients with antiepileptic polypharmacy","author":"Yamamoto","year":"2014","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.jiac.2017.12.022_bib18","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1002\/(SICI)1099-081X(199907)20:5<233::AID-BDD179>3.0.CO;2-5","article-title":"Population estimation of valproic acid clearance in adult patients using routine clinical pharmacokinetic data","volume":"20","author":"Blanco-Serrano","year":"1999","journal-title":"Biopharm Drug Dispos"},{"key":"10.1016\/j.jiac.2017.12.022_bib19","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1248\/bpb.35.487","article-title":"Influence of concomitant antiepileptic drugs on plasma lamotrigine concentration in adult Japanese epilepsy patients","volume":"35","author":"Yamamoto","year":"2012","journal-title":"Biol Pharm Bull"}],"container-title":["Journal of Infection and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X18300102?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X18300102?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T18:57:48Z","timestamp":1761159468000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1341321X18300102"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":19,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["S1341321X18300102"],"URL":"https:\/\/doi.org\/10.1016\/j.jiac.2017.12.022","relation":{},"ISSN":["1341-321X"],"issn-type":[{"value":"1341-321X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A potential drug interaction between phenobarbital and dolutegravir: A case report","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection and Chemotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jiac.2017.12.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}